Climb Bio (NASDAQ:CLYM) is advancing a pipeline of best-in-class, patient-tailored therapeutics to address the unmet needs of complex and clinically-diverse immune-mediated diseases.
Closely-held MOBILion Systems is redefining analytical characterization through its next-generation separation science platform that is integrated with high-resolution mass spectrometry to achieve unprecedented...
Closely-held VICO Therapeutics is developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe genetic neurological diseases, including Huntington’s disease (HD) and spinocerebellar...
IMUNON (NASDAQ:IMNN) is advancing a distinctive approach to treating of some of the world’s most challenging diseases, leveraging a portfolio of proprietary immunology and DNA-based platforms that harness the body’s...
Closely-held GRIN Therapeutics, a Neurvati Neuroscience company, is advancing promising research and development of precision therapeutics for neurodevelopmental disorders, predominately affecting children from infancy...
Perimeter Medical Imaging AI (TSX-V:PINK; OTC:PYNKF) is poised to transform cancer surgery, as positive topline results from a pivotal study designed to support the company’s planned FDA premarket approval (PMA)...
Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...
Spectral Medical (TSX: EDT) is seeking to improve outcomes for millions of patients with life-threatening endotoxic septic shock (ESS), by combining its targeted diagnostic, Endotoxin Activity Assay (EAA), with its...
Closely-held Creyon Bio is developing a faster, more cost-effective path to new medicines for rare and common diseases through the AI-enabled engineering of oligonucleotide-based therapies (OBMs) that deliver safe...